Related Experiment Videos
[Current pharmacotherapy of schizophrenia]
1Semmelweis Egyetem, Altalános Orvostudományi Kar, Pszichiátriai és Pszichoterápiás Klinika. bitter@psych.sote.hu
Orvosi Hetilap
|March 19, 2004
Summary
Second generation antipsychotics are standard schizophrenia treatment, offering better efficacy and fewer side effects than older drugs. Economic barriers remain a significant limitation to their widespread use.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Second-generation antipsychotics (SGAs) represent the current standard in schizophrenia pharmacotherapy.
- Several SGAs, including amisulprid, clozapine, olanzapine, quetiapine, risperidone, sertindol, and ziprasidone, are approved in Hungary.
Purpose of the Study:
- To review the current status and limitations of second-generation antipsychotics in schizophrenia treatment.
- To highlight the advantages of SGAs over first-generation antipsychotics.
Main Methods:
- Literature review of second-generation antipsychotics.
- Analysis of registered antipsychotic drugs in Hungary.
Main Results:
- Second-generation antipsychotics demonstrate superior efficacy compared to first-generation agents.
- Side effect profiles of SGAs are generally less stigmatizing than those of older antipsychotics.
- Key limitations to SGA use include formulation availability, physician experience, and significant economic barriers.
Conclusions:
- Second-generation antipsychotics are integral to modern schizophrenia pharmacotherapy.
- Despite their benefits, economic factors present a major obstacle to their accessibility and optimal utilization.